Last reviewed · How we verify
BALI association
BALI is a fixed-dose combination association designed to treat a specific therapeutic indication through synergistic action of its component drugs.
At a glance
| Generic name | BALI association |
|---|---|
| Sponsor | EMS |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without access to the specific components of the BALI association by EMS, the precise mechanism cannot be accurately described. BALI appears to be a proprietary combination product in Phase 3 development by the Brazilian pharmaceutical company EMS, but the individual active ingredients and their targets are not clearly documented in standard pharmaceutical databases.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of BALI Association in the Treatment of Aphthous Ulcerations (PHASE3)
- A Comprehensive Travel Health Education for Tour Guides in Bali, Indonesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BALI association CI brief — competitive landscape report
- BALI association updates RSS · CI watch RSS
- EMS portfolio CI